nodes	percent_of_prediction	percent_of_DWPC	metapath
Fulvestrant—ESR2—urinary bladder cancer	0.445	0.619	CbGaD
Fulvestrant—ESR1—urinary bladder cancer	0.274	0.381	CbGaD
Fulvestrant—NR1H4—prostate gland—urinary bladder cancer	0.0049	0.0762	CbGeAlD
Fulvestrant—EPHX2—prostate gland—urinary bladder cancer	0.00428	0.0666	CbGeAlD
Fulvestrant—ESRRA—prostate gland—urinary bladder cancer	0.00375	0.0584	CbGeAlD
Fulvestrant—EPHX2—seminal vesicle—urinary bladder cancer	0.00362	0.0564	CbGeAlD
Fulvestrant—NR1H4—renal system—urinary bladder cancer	0.00334	0.052	CbGeAlD
Fulvestrant—ESRRA—seminal vesicle—urinary bladder cancer	0.00317	0.0494	CbGeAlD
Fulvestrant—EPHX2—urethra—urinary bladder cancer	0.00287	0.0446	CbGeAlD
Fulvestrant—NR1H4—female reproductive system—urinary bladder cancer	0.00267	0.0416	CbGeAlD
Fulvestrant—ESRRA—renal system—urinary bladder cancer	0.00256	0.0398	CbGeAlD
Fulvestrant—ESRRA—urethra—urinary bladder cancer	0.00251	0.0391	CbGeAlD
Fulvestrant—CYP3A4—urine—urinary bladder cancer	0.0024	0.0373	CbGeAlD
Fulvestrant—ESR2—prostate gland—urinary bladder cancer	0.00225	0.035	CbGeAlD
Fulvestrant—EPHX2—vagina—urinary bladder cancer	0.00211	0.0329	CbGeAlD
Fulvestrant—ESRRA—female reproductive system—urinary bladder cancer	0.00205	0.0319	CbGeAlD
Fulvestrant—ESRRA—vagina—urinary bladder cancer	0.00185	0.0288	CbGeAlD
Fulvestrant—ESR2—epithelium—urinary bladder cancer	0.00165	0.0257	CbGeAlD
Fulvestrant—ESR2—smooth muscle tissue—urinary bladder cancer	0.00159	0.0248	CbGeAlD
Fulvestrant—NR1H4—lymph node—urinary bladder cancer	0.00156	0.0243	CbGeAlD
Fulvestrant—ESR1—prostate gland—urinary bladder cancer	0.00154	0.024	CbGeAlD
Fulvestrant—ESR2—renal system—urinary bladder cancer	0.00153	0.0239	CbGeAlD
Fulvestrant—EPHX2—lymph node—urinary bladder cancer	0.00137	0.0213	CbGeAlD
Fulvestrant—ESR2—female reproductive system—urinary bladder cancer	0.00123	0.0191	CbGeAlD
Fulvestrant—Estradiol—ESR2—urinary bladder cancer	0.00122	0.619	CrCbGaD
Fulvestrant—ESRRA—lymph node—urinary bladder cancer	0.0012	0.0186	CbGeAlD
Fulvestrant—ESR1—epithelium—urinary bladder cancer	0.00113	0.0176	CbGeAlD
Fulvestrant—ESR2—vagina—urinary bladder cancer	0.00111	0.0173	CbGeAlD
Fulvestrant—ESR1—smooth muscle tissue—urinary bladder cancer	0.00109	0.017	CbGeAlD
Fulvestrant—ESR1—renal system—urinary bladder cancer	0.00105	0.0163	CbGeAlD
Fulvestrant—ESR1—female reproductive system—urinary bladder cancer	0.000842	0.0131	CbGeAlD
Fulvestrant—ESR1—vagina—urinary bladder cancer	0.000761	0.0118	CbGeAlD
Fulvestrant—Estradiol—ESR1—urinary bladder cancer	0.000749	0.381	CrCbGaD
Fulvestrant—ESR2—lymph node—urinary bladder cancer	0.000719	0.0112	CbGeAlD
Fulvestrant—CYP3A4—renal system—urinary bladder cancer	0.000586	0.00912	CbGeAlD
Fulvestrant—ESR1—lymph node—urinary bladder cancer	0.000492	0.00766	CbGeAlD
Fulvestrant—CYP3A4—female reproductive system—urinary bladder cancer	0.00047	0.00731	CbGeAlD
Fulvestrant—Skin disorder—Cisplatin—urinary bladder cancer	0.000192	0.00169	CcSEcCtD
Fulvestrant—Insomnia—Gemcitabine—urinary bladder cancer	0.000191	0.00168	CcSEcCtD
Fulvestrant—Pain in extremity—Doxorubicin—urinary bladder cancer	0.000191	0.00168	CcSEcCtD
Fulvestrant—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000191	0.00168	CcSEcCtD
Fulvestrant—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00019	0.00167	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00019	0.00167	CcSEcCtD
Fulvestrant—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000189	0.00166	CcSEcCtD
Fulvestrant—Chest pain—Etoposide—urinary bladder cancer	0.000189	0.00166	CcSEcCtD
Fulvestrant—Insomnia—Fluorouracil—urinary bladder cancer	0.000188	0.00166	CcSEcCtD
Fulvestrant—Anorexia—Cisplatin—urinary bladder cancer	0.000188	0.00165	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000187	0.00165	CcSEcCtD
Fulvestrant—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000187	0.00164	CcSEcCtD
Fulvestrant—Breast disorder—Epirubicin—urinary bladder cancer	0.000186	0.00164	CcSEcCtD
Fulvestrant—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000186	0.00163	CcSEcCtD
Fulvestrant—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000185	0.00163	CcSEcCtD
Fulvestrant—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000184	0.00162	CcSEcCtD
Fulvestrant—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000183	0.00161	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000183	0.00161	CcSEcCtD
Fulvestrant—Fatigue—Gemcitabine—urinary bladder cancer	0.000182	0.00161	CcSEcCtD
Fulvestrant—Pain—Gemcitabine—urinary bladder cancer	0.000181	0.00159	CcSEcCtD
Fulvestrant—Constipation—Gemcitabine—urinary bladder cancer	0.000181	0.00159	CcSEcCtD
Fulvestrant—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000181	0.00159	CcSEcCtD
Fulvestrant—Asthenia—Thiotepa—urinary bladder cancer	0.000181	0.00159	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00018	0.00158	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00018	0.00158	CcSEcCtD
Fulvestrant—Infection—Etoposide—urinary bladder cancer	0.00018	0.00158	CcSEcCtD
Fulvestrant—Influenza—Epirubicin—urinary bladder cancer	0.000178	0.00157	CcSEcCtD
Fulvestrant—Pruritus—Thiotepa—urinary bladder cancer	0.000178	0.00157	CcSEcCtD
Fulvestrant—Pain—Fluorouracil—urinary bladder cancer	0.000178	0.00157	CcSEcCtD
Fulvestrant—Paraesthesia—Cisplatin—urinary bladder cancer	0.000177	0.00156	CcSEcCtD
Fulvestrant—Dyspnoea—Cisplatin—urinary bladder cancer	0.000176	0.00155	CcSEcCtD
Fulvestrant—Skin disorder—Etoposide—urinary bladder cancer	0.000176	0.00154	CcSEcCtD
Fulvestrant—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000175	0.00154	CcSEcCtD
Fulvestrant—Breast disorder—Doxorubicin—urinary bladder cancer	0.000172	0.00152	CcSEcCtD
Fulvestrant—Anorexia—Etoposide—urinary bladder cancer	0.000172	0.00152	CcSEcCtD
Fulvestrant—Diarrhoea—Thiotepa—urinary bladder cancer	0.000172	0.00151	CcSEcCtD
Fulvestrant—Decreased appetite—Cisplatin—urinary bladder cancer	0.000171	0.00151	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00017	0.0015	CcSEcCtD
Fulvestrant—Infestation—Methotrexate—urinary bladder cancer	0.00017	0.00149	CcSEcCtD
Fulvestrant—Infestation NOS—Methotrexate—urinary bladder cancer	0.00017	0.00149	CcSEcCtD
Fulvestrant—Depression—Methotrexate—urinary bladder cancer	0.000169	0.00149	CcSEcCtD
Fulvestrant—Pain—Cisplatin—urinary bladder cancer	0.000169	0.00148	CcSEcCtD
Fulvestrant—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000167	0.00147	CcSEcCtD
Fulvestrant—Dizziness—Thiotepa—urinary bladder cancer	0.000166	0.00146	CcSEcCtD
Fulvestrant—Urticaria—Fluorouracil—urinary bladder cancer	0.000165	0.00145	CcSEcCtD
Fulvestrant—Influenza—Doxorubicin—urinary bladder cancer	0.000165	0.00145	CcSEcCtD
Fulvestrant—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000165	0.00145	CcSEcCtD
Fulvestrant—Sweating—Methotrexate—urinary bladder cancer	0.000163	0.00143	CcSEcCtD
Fulvestrant—Paraesthesia—Etoposide—urinary bladder cancer	0.000162	0.00143	CcSEcCtD
Fulvestrant—Dyspnoea—Etoposide—urinary bladder cancer	0.000161	0.00142	CcSEcCtD
Fulvestrant—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000161	0.00141	CcSEcCtD
Fulvestrant—Vomiting—Thiotepa—urinary bladder cancer	0.00016	0.00141	CcSEcCtD
Fulvestrant—Infestation—Epirubicin—urinary bladder cancer	0.000159	0.0014	CcSEcCtD
Fulvestrant—Infestation NOS—Epirubicin—urinary bladder cancer	0.000159	0.0014	CcSEcCtD
Fulvestrant—Rash—Thiotepa—urinary bladder cancer	0.000159	0.0014	CcSEcCtD
Fulvestrant—Dermatitis—Thiotepa—urinary bladder cancer	0.000158	0.00139	CcSEcCtD
Fulvestrant—Headache—Thiotepa—urinary bladder cancer	0.000158	0.00139	CcSEcCtD
Fulvestrant—Decreased appetite—Etoposide—urinary bladder cancer	0.000157	0.00138	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000156	0.00137	CcSEcCtD
Fulvestrant—Body temperature increased—Cisplatin—urinary bladder cancer	0.000156	0.00137	CcSEcCtD
Fulvestrant—Fatigue—Etoposide—urinary bladder cancer	0.000156	0.00137	CcSEcCtD
Fulvestrant—Pain—Etoposide—urinary bladder cancer	0.000155	0.00136	CcSEcCtD
Fulvestrant—Constipation—Etoposide—urinary bladder cancer	0.000155	0.00136	CcSEcCtD
Fulvestrant—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000154	0.00136	CcSEcCtD
Fulvestrant—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000153	0.00135	CcSEcCtD
Fulvestrant—Haemoglobin—Methotrexate—urinary bladder cancer	0.000153	0.00135	CcSEcCtD
Fulvestrant—Haemorrhage—Methotrexate—urinary bladder cancer	0.000152	0.00134	CcSEcCtD
Fulvestrant—Hepatitis—Methotrexate—urinary bladder cancer	0.000152	0.00134	CcSEcCtD
Fulvestrant—Sweating—Epirubicin—urinary bladder cancer	0.000152	0.00134	CcSEcCtD
Fulvestrant—Asthenia—Gemcitabine—urinary bladder cancer	0.000152	0.00134	CcSEcCtD
Fulvestrant—Pharyngitis—Methotrexate—urinary bladder cancer	0.000151	0.00133	CcSEcCtD
Fulvestrant—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.00015	0.00132	CcSEcCtD
Fulvestrant—Pruritus—Gemcitabine—urinary bladder cancer	0.00015	0.00132	CcSEcCtD
Fulvestrant—Nausea—Thiotepa—urinary bladder cancer	0.000149	0.00132	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000148	0.0013	CcSEcCtD
Fulvestrant—Pruritus—Fluorouracil—urinary bladder cancer	0.000147	0.0013	CcSEcCtD
Fulvestrant—Infestation—Doxorubicin—urinary bladder cancer	0.000147	0.00129	CcSEcCtD
Fulvestrant—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000147	0.00129	CcSEcCtD
Fulvestrant—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000145	0.00128	CcSEcCtD
Fulvestrant—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000145	0.00127	CcSEcCtD
Fulvestrant—Urticaria—Etoposide—urinary bladder cancer	0.000144	0.00126	CcSEcCtD
Fulvestrant—Haemoglobin—Epirubicin—urinary bladder cancer	0.000143	0.00126	CcSEcCtD
Fulvestrant—Abdominal pain—Etoposide—urinary bladder cancer	0.000143	0.00126	CcSEcCtD
Fulvestrant—Body temperature increased—Etoposide—urinary bladder cancer	0.000143	0.00126	CcSEcCtD
Fulvestrant—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000143	0.00126	CcSEcCtD
Fulvestrant—Hepatitis—Epirubicin—urinary bladder cancer	0.000143	0.00125	CcSEcCtD
Fulvestrant—Haemorrhage—Epirubicin—urinary bladder cancer	0.000143	0.00125	CcSEcCtD
Fulvestrant—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000142	0.00125	CcSEcCtD
Fulvestrant—Asthenia—Cisplatin—urinary bladder cancer	0.000142	0.00125	CcSEcCtD
Fulvestrant—Pharyngitis—Epirubicin—urinary bladder cancer	0.000142	0.00125	CcSEcCtD
Fulvestrant—Sweating—Doxorubicin—urinary bladder cancer	0.000141	0.00124	CcSEcCtD
Fulvestrant—Oedema peripheral—Epirubicin—urinary bladder cancer	0.00014	0.00124	CcSEcCtD
Fulvestrant—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.00014	0.00123	CcSEcCtD
Fulvestrant—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000139	0.00122	CcSEcCtD
Fulvestrant—Angiopathy—Methotrexate—urinary bladder cancer	0.000138	0.00122	CcSEcCtD
Fulvestrant—Immune system disorder—Methotrexate—urinary bladder cancer	0.000138	0.00121	CcSEcCtD
Fulvestrant—Dizziness—Fluorouracil—urinary bladder cancer	0.000138	0.00121	CcSEcCtD
Fulvestrant—Diarrhoea—Cisplatin—urinary bladder cancer	0.000135	0.00119	CcSEcCtD
Fulvestrant—Vomiting—Gemcitabine—urinary bladder cancer	0.000135	0.00118	CcSEcCtD
Fulvestrant—Rash—Gemcitabine—urinary bladder cancer	0.000133	0.00117	CcSEcCtD
Fulvestrant—Dermatitis—Gemcitabine—urinary bladder cancer	0.000133	0.00117	CcSEcCtD
Fulvestrant—Hypersensitivity—Etoposide—urinary bladder cancer	0.000133	0.00117	CcSEcCtD
Fulvestrant—Malnutrition—Methotrexate—urinary bladder cancer	0.000133	0.00117	CcSEcCtD
Fulvestrant—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000133	0.00117	CcSEcCtD
Fulvestrant—Headache—Gemcitabine—urinary bladder cancer	0.000133	0.00117	CcSEcCtD
Fulvestrant—Vomiting—Fluorouracil—urinary bladder cancer	0.000132	0.00116	CcSEcCtD
Fulvestrant—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000132	0.00116	CcSEcCtD
Fulvestrant—Hepatitis—Doxorubicin—urinary bladder cancer	0.000132	0.00116	CcSEcCtD
Fulvestrant—Rash—Fluorouracil—urinary bladder cancer	0.000131	0.00115	CcSEcCtD
Fulvestrant—Dermatitis—Fluorouracil—urinary bladder cancer	0.000131	0.00115	CcSEcCtD
Fulvestrant—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000131	0.00115	CcSEcCtD
Fulvestrant—Headache—Fluorouracil—urinary bladder cancer	0.00013	0.00115	CcSEcCtD
Fulvestrant—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.00013	0.00114	CcSEcCtD
Fulvestrant—Asthenia—Etoposide—urinary bladder cancer	0.00013	0.00114	CcSEcCtD
Fulvestrant—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.00013	0.00114	CcSEcCtD
Fulvestrant—Angiopathy—Epirubicin—urinary bladder cancer	0.000129	0.00114	CcSEcCtD
Fulvestrant—Immune system disorder—Epirubicin—urinary bladder cancer	0.000129	0.00113	CcSEcCtD
Fulvestrant—Back pain—Methotrexate—urinary bladder cancer	0.000128	0.00113	CcSEcCtD
Fulvestrant—Pruritus—Etoposide—urinary bladder cancer	0.000128	0.00113	CcSEcCtD
Fulvestrant—Nausea—Gemcitabine—urinary bladder cancer	0.000126	0.00111	CcSEcCtD
Fulvestrant—Vomiting—Cisplatin—urinary bladder cancer	0.000125	0.0011	CcSEcCtD
Fulvestrant—Rash—Cisplatin—urinary bladder cancer	0.000124	0.00109	CcSEcCtD
Fulvestrant—Dermatitis—Cisplatin—urinary bladder cancer	0.000124	0.00109	CcSEcCtD
Fulvestrant—Malnutrition—Epirubicin—urinary bladder cancer	0.000124	0.00109	CcSEcCtD
Fulvestrant—Diarrhoea—Etoposide—urinary bladder cancer	0.000124	0.00109	CcSEcCtD
Fulvestrant—Nausea—Fluorouracil—urinary bladder cancer	0.000124	0.00109	CcSEcCtD
Fulvestrant—Anaemia—Methotrexate—urinary bladder cancer	0.000123	0.00108	CcSEcCtD
Fulvestrant—Back pain—Epirubicin—urinary bladder cancer	0.00012	0.00106	CcSEcCtD
Fulvestrant—Angiopathy—Doxorubicin—urinary bladder cancer	0.00012	0.00105	CcSEcCtD
Fulvestrant—Dizziness—Etoposide—urinary bladder cancer	0.00012	0.00105	CcSEcCtD
Fulvestrant—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000119	0.00105	CcSEcCtD
Fulvestrant—Vertigo—Methotrexate—urinary bladder cancer	0.000119	0.00105	CcSEcCtD
Fulvestrant—Leukopenia—Methotrexate—urinary bladder cancer	0.000119	0.00104	CcSEcCtD
Fulvestrant—Nausea—Cisplatin—urinary bladder cancer	0.000117	0.00103	CcSEcCtD
Fulvestrant—Cough—Methotrexate—urinary bladder cancer	0.000116	0.00102	CcSEcCtD
Fulvestrant—Vomiting—Etoposide—urinary bladder cancer	0.000115	0.00101	CcSEcCtD
Fulvestrant—Malnutrition—Doxorubicin—urinary bladder cancer	0.000115	0.00101	CcSEcCtD
Fulvestrant—Anaemia—Epirubicin—urinary bladder cancer	0.000115	0.00101	CcSEcCtD
Fulvestrant—Rash—Etoposide—urinary bladder cancer	0.000114	0.001	CcSEcCtD
Fulvestrant—Dermatitis—Etoposide—urinary bladder cancer	0.000114	0.001	CcSEcCtD
Fulvestrant—Headache—Etoposide—urinary bladder cancer	0.000113	0.000996	CcSEcCtD
Fulvestrant—Chest pain—Methotrexate—urinary bladder cancer	0.000113	0.000994	CcSEcCtD
Fulvestrant—Myalgia—Methotrexate—urinary bladder cancer	0.000113	0.000994	CcSEcCtD
Fulvestrant—Arthralgia—Methotrexate—urinary bladder cancer	0.000113	0.000994	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000112	0.000987	CcSEcCtD
Fulvestrant—Vertigo—Epirubicin—urinary bladder cancer	0.000112	0.000981	CcSEcCtD
Fulvestrant—Leukopenia—Epirubicin—urinary bladder cancer	0.000111	0.000978	CcSEcCtD
Fulvestrant—Back pain—Doxorubicin—urinary bladder cancer	0.000111	0.000978	CcSEcCtD
Fulvestrant—Cough—Epirubicin—urinary bladder cancer	0.000108	0.000953	CcSEcCtD
Fulvestrant—Infection—Methotrexate—urinary bladder cancer	0.000108	0.000946	CcSEcCtD
Fulvestrant—Nausea—Etoposide—urinary bladder cancer	0.000107	0.000945	CcSEcCtD
Fulvestrant—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000106	0.000934	CcSEcCtD
Fulvestrant—Anaemia—Doxorubicin—urinary bladder cancer	0.000106	0.000934	CcSEcCtD
Fulvestrant—Arthralgia—Epirubicin—urinary bladder cancer	0.000106	0.00093	CcSEcCtD
Fulvestrant—Chest pain—Epirubicin—urinary bladder cancer	0.000106	0.00093	CcSEcCtD
Fulvestrant—Myalgia—Epirubicin—urinary bladder cancer	0.000106	0.00093	CcSEcCtD
Fulvestrant—Anxiety—Epirubicin—urinary bladder cancer	0.000105	0.000927	CcSEcCtD
Fulvestrant—Skin disorder—Methotrexate—urinary bladder cancer	0.000105	0.000925	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000105	0.000924	CcSEcCtD
Fulvestrant—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000105	0.000921	CcSEcCtD
Fulvestrant—Vertigo—Doxorubicin—urinary bladder cancer	0.000103	0.000908	CcSEcCtD
Fulvestrant—Anorexia—Methotrexate—urinary bladder cancer	0.000103	0.000908	CcSEcCtD
Fulvestrant—Leukopenia—Doxorubicin—urinary bladder cancer	0.000103	0.000905	CcSEcCtD
Fulvestrant—ESR1—Regulation of Telomerase—CCND1—urinary bladder cancer	0.000101	0.001	CbGpPWpGaD
Fulvestrant—Infection—Epirubicin—urinary bladder cancer	0.000101	0.000886	CcSEcCtD
Fulvestrant—Cough—Doxorubicin—urinary bladder cancer	0.0001	0.000882	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	9.96e-05	0.000987	CbGpPWpGaD
Fulvestrant—Nervous system disorder—Epirubicin—urinary bladder cancer	9.93e-05	0.000874	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—GSTT1—urinary bladder cancer	9.91e-05	0.000982	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—CCND1—urinary bladder cancer	9.91e-05	0.000982	CbGpPWpGaD
Fulvestrant—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	9.86e-05	0.000868	CcSEcCtD
Fulvestrant—NR1H4—Generic Transcription Pathway—NCOR1—urinary bladder cancer	9.86e-05	0.000977	CbGpPWpGaD
Fulvestrant—Skin disorder—Epirubicin—urinary bladder cancer	9.84e-05	0.000866	CcSEcCtD
Fulvestrant—ESR1—Validated nuclear estrogen receptor alpha network—EP300—urinary bladder cancer	9.8e-05	0.000971	CbGpPWpGaD
Fulvestrant—Hyperhidrosis—Epirubicin—urinary bladder cancer	9.79e-05	0.000862	CcSEcCtD
Fulvestrant—Insomnia—Methotrexate—urinary bladder cancer	9.79e-05	0.000862	CcSEcCtD
Fulvestrant—Chest pain—Doxorubicin—urinary bladder cancer	9.78e-05	0.000861	CcSEcCtD
Fulvestrant—Arthralgia—Doxorubicin—urinary bladder cancer	9.78e-05	0.000861	CcSEcCtD
Fulvestrant—Myalgia—Doxorubicin—urinary bladder cancer	9.78e-05	0.000861	CcSEcCtD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	9.76e-05	0.000967	CbGpPWpGaD
Fulvestrant—NR1H4—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	9.75e-05	0.000967	CbGpPWpGaD
Fulvestrant—Anxiety—Doxorubicin—urinary bladder cancer	9.74e-05	0.000858	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	9.74e-05	0.000965	CbGpPWpGaD
Fulvestrant—Paraesthesia—Methotrexate—urinary bladder cancer	9.72e-05	0.000855	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	9.71e-05	0.000855	CcSEcCtD
Fulvestrant—ESRRA—Generic Transcription Pathway—PPARG—urinary bladder cancer	9.66e-05	0.000958	CbGpPWpGaD
Fulvestrant—Anorexia—Epirubicin—urinary bladder cancer	9.66e-05	0.00085	CcSEcCtD
Fulvestrant—Dyspnoea—Methotrexate—urinary bladder cancer	9.65e-05	0.000849	CcSEcCtD
Fulvestrant—ESRRA—Gene Expression—SMC1A—urinary bladder cancer	9.65e-05	0.000956	CbGpPWpGaD
Fulvestrant—ESR1—LKB1 signaling events—TP53—urinary bladder cancer	9.64e-05	0.000955	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—MMP9—urinary bladder cancer	9.62e-05	0.000953	CbGpPWpGaD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—HRAS—urinary bladder cancer	9.57e-05	0.000949	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—PTEN—urinary bladder cancer	9.56e-05	0.000947	CbGpPWpGaD
Fulvestrant—Dyspepsia—Methotrexate—urinary bladder cancer	9.53e-05	0.000839	CcSEcCtD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	9.52e-05	0.000944	CbGpPWpGaD
Fulvestrant—Decreased appetite—Methotrexate—urinary bladder cancer	9.41e-05	0.000828	CcSEcCtD
Fulvestrant—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	9.4e-05	0.000931	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—CCND1—urinary bladder cancer	9.37e-05	0.000929	CbGpPWpGaD
Fulvestrant—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	9.35e-05	0.000822	CcSEcCtD
Fulvestrant—Fatigue—Methotrexate—urinary bladder cancer	9.33e-05	0.000821	CcSEcCtD
Fulvestrant—Infection—Doxorubicin—urinary bladder cancer	9.31e-05	0.00082	CcSEcCtD
Fulvestrant—ESRRA—Generic Transcription Pathway—CREBBP—urinary bladder cancer	9.28e-05	0.00092	CbGpPWpGaD
Fulvestrant—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	9.27e-05	0.000918	CbGpPWpGaD
Fulvestrant—Pain—Methotrexate—urinary bladder cancer	9.26e-05	0.000815	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	9.23e-05	0.000812	CcSEcCtD
Fulvestrant—Nervous system disorder—Doxorubicin—urinary bladder cancer	9.19e-05	0.000809	CcSEcCtD
Fulvestrant—Insomnia—Epirubicin—urinary bladder cancer	9.16e-05	0.000806	CcSEcCtD
Fulvestrant—ESR1—AP-1 transcription factor network—EP300—urinary bladder cancer	9.12e-05	0.000904	CbGpPWpGaD
Fulvestrant—Skin disorder—Doxorubicin—urinary bladder cancer	9.1e-05	0.000801	CcSEcCtD
Fulvestrant—Paraesthesia—Epirubicin—urinary bladder cancer	9.1e-05	0.000801	CcSEcCtD
Fulvestrant—Hyperhidrosis—Doxorubicin—urinary bladder cancer	9.06e-05	0.000797	CcSEcCtD
Fulvestrant—Dyspnoea—Epirubicin—urinary bladder cancer	9.03e-05	0.000795	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	8.97e-05	0.000889	CbGpPWpGaD
Fulvestrant—Anorexia—Doxorubicin—urinary bladder cancer	8.94e-05	0.000786	CcSEcCtD
Fulvestrant—Dyspepsia—Epirubicin—urinary bladder cancer	8.92e-05	0.000785	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Methotrexate—urinary bladder cancer	8.85e-05	0.000779	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—RRM2—urinary bladder cancer	8.82e-05	0.000874	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	8.81e-05	0.000873	CbGpPWpGaD
Fulvestrant—Decreased appetite—Epirubicin—urinary bladder cancer	8.81e-05	0.000775	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	8.8e-05	0.000872	CbGpPWpGaD
Fulvestrant—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	8.75e-05	0.00077	CcSEcCtD
Fulvestrant—Fatigue—Epirubicin—urinary bladder cancer	8.73e-05	0.000769	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	8.73e-05	0.000865	CbGpPWpGaD
Fulvestrant—Constipation—Epirubicin—urinary bladder cancer	8.66e-05	0.000762	CcSEcCtD
Fulvestrant—Pain—Epirubicin—urinary bladder cancer	8.66e-05	0.000762	CcSEcCtD
Fulvestrant—Urticaria—Methotrexate—urinary bladder cancer	8.6e-05	0.000757	CcSEcCtD
Fulvestrant—ESR2—Generic Transcription Pathway—NCOR1—urinary bladder cancer	8.58e-05	0.00085	CbGpPWpGaD
Fulvestrant—Abdominal pain—Methotrexate—urinary bladder cancer	8.56e-05	0.000753	CcSEcCtD
Fulvestrant—Body temperature increased—Methotrexate—urinary bladder cancer	8.56e-05	0.000753	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	8.54e-05	0.000752	CcSEcCtD
Fulvestrant—ESR1—Validated nuclear estrogen receptor alpha network—MYC—urinary bladder cancer	8.54e-05	0.000846	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—urinary bladder cancer	8.53e-05	0.000845	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	8.51e-05	0.000844	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	8.49e-05	0.000842	CbGpPWpGaD
Fulvestrant—Insomnia—Doxorubicin—urinary bladder cancer	8.48e-05	0.000746	CcSEcCtD
Fulvestrant—ESR1—Signaling by ERBB4—FGFR3—urinary bladder cancer	8.46e-05	0.000838	CbGpPWpGaD
Fulvestrant—Paraesthesia—Doxorubicin—urinary bladder cancer	8.42e-05	0.000741	CcSEcCtD
Fulvestrant—ESRRA—Gene Expression—ESR2—urinary bladder cancer	8.41e-05	0.000833	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—SRC—urinary bladder cancer	8.39e-05	0.000831	CbGpPWpGaD
Fulvestrant—Dyspnoea—Doxorubicin—urinary bladder cancer	8.36e-05	0.000735	CcSEcCtD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—ATM—urinary bladder cancer	8.33e-05	0.000825	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CDK4—urinary bladder cancer	8.29e-05	0.000822	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	8.28e-05	0.000821	CbGpPWpGaD
Fulvestrant—Gastrointestinal pain—Epirubicin—urinary bladder cancer	8.28e-05	0.000729	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—TYMP—urinary bladder cancer	8.26e-05	0.000818	CbGpPWpGaD
Fulvestrant—Dyspepsia—Doxorubicin—urinary bladder cancer	8.25e-05	0.000726	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—NQO1—urinary bladder cancer	8.24e-05	0.000816	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—ENO2—urinary bladder cancer	8.17e-05	0.00081	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—HPGDS—urinary bladder cancer	8.17e-05	0.00081	CbGpPWpGaD
Fulvestrant—Decreased appetite—Doxorubicin—urinary bladder cancer	8.15e-05	0.000717	CcSEcCtD
Fulvestrant—ESR1—Regulation of Telomerase—MYC—urinary bladder cancer	8.13e-05	0.000806	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	8.12e-05	0.000805	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—EP300—urinary bladder cancer	8.11e-05	0.000804	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	8.1e-05	0.000803	CbGpPWpGaD
Fulvestrant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	8.1e-05	0.000802	CbGpPWpGaD
Fulvestrant—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	8.09e-05	0.000712	CcSEcCtD
Fulvestrant—Fatigue—Doxorubicin—urinary bladder cancer	8.08e-05	0.000711	CcSEcCtD
Fulvestrant—Urticaria—Epirubicin—urinary bladder cancer	8.05e-05	0.000708	CcSEcCtD
Fulvestrant—Constipation—Doxorubicin—urinary bladder cancer	8.02e-05	0.000705	CcSEcCtD
Fulvestrant—Pain—Doxorubicin—urinary bladder cancer	8.02e-05	0.000705	CcSEcCtD
Fulvestrant—Body temperature increased—Epirubicin—urinary bladder cancer	8.01e-05	0.000705	CcSEcCtD
Fulvestrant—Abdominal pain—Epirubicin—urinary bladder cancer	8.01e-05	0.000705	CcSEcCtD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	7.99e-05	0.000792	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Methotrexate—urinary bladder cancer	7.98e-05	0.000702	CcSEcCtD
Fulvestrant—ESR1—Regulation of Telomerase—EGFR—urinary bladder cancer	7.95e-05	0.000788	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—MYC—urinary bladder cancer	7.95e-05	0.000787	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	7.93e-05	0.000786	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—GSTT1—urinary bladder cancer	7.93e-05	0.000785	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	7.88e-05	0.000781	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	7.81e-05	0.000774	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	7.8e-05	0.000773	CbGpPWpGaD
Fulvestrant—Asthenia—Methotrexate—urinary bladder cancer	7.77e-05	0.000684	CcSEcCtD
Fulvestrant—NR1H4—Generic Transcription Pathway—ESR1—urinary bladder cancer	7.74e-05	0.000767	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	7.73e-05	0.000766	CbGpPWpGaD
Fulvestrant—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	7.67e-05	0.000675	CcSEcCtD
Fulvestrant—Pruritus—Methotrexate—urinary bladder cancer	7.66e-05	0.000674	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—NAT2—urinary bladder cancer	7.47e-05	0.00074	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Epirubicin—urinary bladder cancer	7.46e-05	0.000657	CcSEcCtD
Fulvestrant—Urticaria—Doxorubicin—urinary bladder cancer	7.45e-05	0.000655	CcSEcCtD
Fulvestrant—Abdominal pain—Doxorubicin—urinary bladder cancer	7.41e-05	0.000652	CcSEcCtD
Fulvestrant—Body temperature increased—Doxorubicin—urinary bladder cancer	7.41e-05	0.000652	CcSEcCtD
Fulvestrant—Diarrhoea—Methotrexate—urinary bladder cancer	7.41e-05	0.000652	CcSEcCtD
Fulvestrant—Asthenia—Epirubicin—urinary bladder cancer	7.27e-05	0.00064	CcSEcCtD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—RB1—urinary bladder cancer	7.21e-05	0.000715	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CDH1—urinary bladder cancer	7.18e-05	0.000712	CbGpPWpGaD
Fulvestrant—Pruritus—Epirubicin—urinary bladder cancer	7.17e-05	0.000631	CcSEcCtD
Fulvestrant—Dizziness—Methotrexate—urinary bladder cancer	7.16e-05	0.00063	CcSEcCtD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—MYC—urinary bladder cancer	7.07e-05	0.000701	CbGpPWpGaD
Fulvestrant—NR1H4—Generic Transcription Pathway—PPARG—urinary bladder cancer	7.06e-05	0.0007	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	7.06e-05	0.000699	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—SMC1A—urinary bladder cancer	7.05e-05	0.000699	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.97e-05	0.000691	CbGpPWpGaD
Fulvestrant—Diarrhoea—Epirubicin—urinary bladder cancer	6.93e-05	0.00061	CcSEcCtD
Fulvestrant—Hypersensitivity—Doxorubicin—urinary bladder cancer	6.91e-05	0.000608	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	6.9e-05	0.000684	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	6.9e-05	0.000684	CbGpPWpGaD
Fulvestrant—Vomiting—Methotrexate—urinary bladder cancer	6.88e-05	0.000606	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—GSTP1—urinary bladder cancer	6.87e-05	0.000681	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	6.87e-05	0.000681	CbGpPWpGaD
Fulvestrant—Rash—Methotrexate—urinary bladder cancer	6.83e-05	0.000601	CcSEcCtD
Fulvestrant—Dermatitis—Methotrexate—urinary bladder cancer	6.82e-05	0.0006	CcSEcCtD
Fulvestrant—NR1H4—Generic Transcription Pathway—CREBBP—urinary bladder cancer	6.78e-05	0.000672	CbGpPWpGaD
Fulvestrant—Headache—Methotrexate—urinary bladder cancer	6.78e-05	0.000597	CcSEcCtD
Fulvestrant—ESR2—Generic Transcription Pathway—ESR1—urinary bladder cancer	6.74e-05	0.000668	CbGpPWpGaD
Fulvestrant—Asthenia—Doxorubicin—urinary bladder cancer	6.73e-05	0.000592	CcSEcCtD
Fulvestrant—Dizziness—Epirubicin—urinary bladder cancer	6.7e-05	0.00059	CcSEcCtD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.65e-05	0.000659	CbGpPWpGaD
Fulvestrant—Pruritus—Doxorubicin—urinary bladder cancer	6.63e-05	0.000584	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—NQO1—urinary bladder cancer	6.59e-05	0.000653	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	6.58e-05	0.000652	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—TP53—urinary bladder cancer	6.53e-05	0.000647	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	6.52e-05	0.000646	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—NCOR1—urinary bladder cancer	6.49e-05	0.000643	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—RRM2—urinary bladder cancer	6.45e-05	0.000639	CbGpPWpGaD
Fulvestrant—Vomiting—Epirubicin—urinary bladder cancer	6.44e-05	0.000567	CcSEcCtD
Fulvestrant—Nausea—Methotrexate—urinary bladder cancer	6.43e-05	0.000566	CcSEcCtD
Fulvestrant—Diarrhoea—Doxorubicin—urinary bladder cancer	6.41e-05	0.000564	CcSEcCtD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	6.39e-05	0.000633	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—TYMS—urinary bladder cancer	6.39e-05	0.000633	CbGpPWpGaD
Fulvestrant—Rash—Epirubicin—urinary bladder cancer	6.39e-05	0.000562	CcSEcCtD
Fulvestrant—Dermatitis—Epirubicin—urinary bladder cancer	6.38e-05	0.000562	CcSEcCtD
Fulvestrant—Headache—Epirubicin—urinary bladder cancer	6.35e-05	0.000559	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—GSTM1—urinary bladder cancer	6.32e-05	0.000626	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—NCOR1—urinary bladder cancer	6.32e-05	0.000626	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	6.25e-05	0.00062	CbGpPWpGaD
Fulvestrant—Dizziness—Doxorubicin—urinary bladder cancer	6.2e-05	0.000546	CcSEcCtD
Fulvestrant—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	6.17e-05	0.000611	CbGpPWpGaD
Fulvestrant—ESR2—Generic Transcription Pathway—PPARG—urinary bladder cancer	6.15e-05	0.000609	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—ESR2—urinary bladder cancer	6.15e-05	0.000609	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—SMC1A—urinary bladder cancer	6.14e-05	0.000608	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—ERCC2—urinary bladder cancer	6.1e-05	0.000605	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—GPX1—urinary bladder cancer	6.05e-05	0.000599	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—ERBB2—urinary bladder cancer	6.03e-05	0.000597	CbGpPWpGaD
Fulvestrant—Nausea—Epirubicin—urinary bladder cancer	6.02e-05	0.00053	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	6e-05	0.000594	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—ENO2—urinary bladder cancer	5.97e-05	0.000592	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—HPGDS—urinary bladder cancer	5.97e-05	0.000592	CbGpPWpGaD
Fulvestrant—Vomiting—Doxorubicin—urinary bladder cancer	5.96e-05	0.000525	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—ERCC2—urinary bladder cancer	5.94e-05	0.000588	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.94e-05	0.000588	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	5.92e-05	0.000587	CbGpPWpGaD
Fulvestrant—Rash—Doxorubicin—urinary bladder cancer	5.91e-05	0.00052	CcSEcCtD
Fulvestrant—ESR2—Generic Transcription Pathway—CREBBP—urinary bladder cancer	5.91e-05	0.000585	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—HRAS—urinary bladder cancer	5.91e-05	0.000585	CbGpPWpGaD
Fulvestrant—Dermatitis—Doxorubicin—urinary bladder cancer	5.9e-05	0.00052	CcSEcCtD
Fulvestrant—Headache—Doxorubicin—urinary bladder cancer	5.87e-05	0.000517	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	5.8e-05	0.000574	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—GSTT1—urinary bladder cancer	5.79e-05	0.000574	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.7e-05	0.000565	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—ESR2—urinary bladder cancer	5.6e-05	0.000555	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—MTHFR—urinary bladder cancer	5.58e-05	0.000553	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.57e-05	0.000552	CbGpPWpGaD
Fulvestrant—Nausea—Doxorubicin—urinary bladder cancer	5.57e-05	0.00049	CcSEcCtD
Fulvestrant—ESRRA—Generic Transcription Pathway—MYC—urinary bladder cancer	5.51e-05	0.000546	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—GSTP1—urinary bladder cancer	5.49e-05	0.000544	CbGpPWpGaD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.42e-05	0.000537	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CCND1—urinary bladder cancer	5.36e-05	0.000531	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.32e-05	0.000527	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—PTEN—urinary bladder cancer	5.17e-05	0.000512	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—CDKN1A—urinary bladder cancer	5.15e-05	0.000511	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—PTEN—urinary bladder cancer	5.14e-05	0.00051	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—TYMS—urinary bladder cancer	5.11e-05	0.000506	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—ESR1—urinary bladder cancer	5.1e-05	0.000505	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—GSTM1—urinary bladder cancer	5.05e-05	0.0005	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—NCOR1—urinary bladder cancer	5.05e-05	0.0005	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	5.02e-05	0.000498	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	5e-05	0.000495	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—EP300—urinary bladder cancer	4.93e-05	0.000488	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	4.91e-05	0.000487	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	4.85e-05	0.00048	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—GPX1—urinary bladder cancer	4.83e-05	0.000479	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—NQO1—urinary bladder cancer	4.81e-05	0.000477	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—ERCC2—urinary bladder cancer	4.75e-05	0.00047	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—NCOR1—urinary bladder cancer	4.74e-05	0.00047	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.67e-05	0.000463	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—PPARG—urinary bladder cancer	4.65e-05	0.000461	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PPARG—urinary bladder cancer	4.53e-05	0.000448	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—CREBBP—urinary bladder cancer	4.47e-05	0.000443	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—MTHFR—urinary bladder cancer	4.46e-05	0.000442	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—ERCC2—urinary bladder cancer	4.46e-05	0.000442	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	4.44e-05	0.00044	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—CREBBP—urinary bladder cancer	4.35e-05	0.000431	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—NCOR1—urinary bladder cancer	4.33e-05	0.000429	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—MYC—urinary bladder cancer	4.3e-05	0.000426	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	4.29e-05	0.000425	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	4.28e-05	0.000424	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—EGFR—urinary bladder cancer	4.2e-05	0.000416	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—EGFR—urinary bladder cancer	4.18e-05	0.000414	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—NCOR1—urinary bladder cancer	4.13e-05	0.000409	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	4.08e-05	0.000405	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.07e-05	0.000404	CbGpPWpGaD
Fulvestrant—NR1H4—Generic Transcription Pathway—MYC—urinary bladder cancer	4.03e-05	0.000399	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—GSTP1—urinary bladder cancer	4.01e-05	0.000398	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	3.97e-05	0.000394	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—KRAS—urinary bladder cancer	3.97e-05	0.000393	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—KRAS—urinary bladder cancer	3.95e-05	0.000391	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—ERCC2—urinary bladder cancer	3.88e-05	0.000385	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.88e-05	0.000385	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—TYMS—urinary bladder cancer	3.73e-05	0.00037	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—ESR1—urinary bladder cancer	3.73e-05	0.000369	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—NCOR1—urinary bladder cancer	3.69e-05	0.000366	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—GSTM1—urinary bladder cancer	3.69e-05	0.000366	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—HDAC4—urinary bladder cancer	3.62e-05	0.000359	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PPARG—urinary bladder cancer	3.62e-05	0.000359	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PTGS2—urinary bladder cancer	3.56e-05	0.000353	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	3.56e-05	0.000353	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—GPX1—urinary bladder cancer	3.53e-05	0.00035	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	3.53e-05	0.00035	CbGpPWpGaD
Fulvestrant—ESR2—Generic Transcription Pathway—MYC—urinary bladder cancer	3.51e-05	0.000347	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	3.48e-05	0.000345	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—CREBBP—urinary bladder cancer	3.48e-05	0.000344	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—ERCC2—urinary bladder cancer	3.47e-05	0.000344	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—PPARG—urinary bladder cancer	3.4e-05	0.000337	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	3.36e-05	0.000333	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—HRAS—urinary bladder cancer	3.36e-05	0.000333	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	3.32e-05	0.000329	CbGpPWpGaD
Fulvestrant—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.31e-05	0.000328	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.29e-05	0.000326	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—CREBBP—urinary bladder cancer	3.27e-05	0.000324	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—MTHFR—urinary bladder cancer	3.26e-05	0.000323	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—ESR1—urinary bladder cancer	3.25e-05	0.000322	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PTEN—urinary bladder cancer	3.1e-05	0.000308	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—PPARG—urinary bladder cancer	3.1e-05	0.000307	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—SMC1A—urinary bladder cancer	3.1e-05	0.000307	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	3.09e-05	0.000306	CbGpPWpGaD
Fulvestrant—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.05e-05	0.000302	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—GLI1—urinary bladder cancer	3.03e-05	0.000301	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—CREBBP—urinary bladder cancer	2.98e-05	0.000295	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—PPARG—urinary bladder cancer	2.96e-05	0.000293	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—EP300—urinary bladder cancer	2.96e-05	0.000293	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.92e-05	0.00029	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PTGS2—urinary bladder cancer	2.85e-05	0.000282	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—CREBBP—urinary bladder cancer	2.84e-05	0.000282	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—ESR2—urinary bladder cancer	2.7e-05	0.000267	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—MYC—urinary bladder cancer	2.65e-05	0.000263	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PPARG—urinary bladder cancer	2.64e-05	0.000262	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—CREBBP—urinary bladder cancer	2.54e-05	0.000252	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PTEN—urinary bladder cancer	2.48e-05	0.000246	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—EP300—urinary bladder cancer	2.37e-05	0.000235	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—NCOR1—urinary bladder cancer	2.08e-05	0.000206	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PTGS2—urinary bladder cancer	2.08e-05	0.000206	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—RBX1—urinary bladder cancer	2.08e-05	0.000206	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	2.06e-05	0.000204	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—ERCC2—urinary bladder cancer	1.96e-05	0.000194	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TSC1—urinary bladder cancer	1.95e-05	0.000194	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.95e-05	0.000193	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.95e-05	0.000193	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—MYC—urinary bladder cancer	1.94e-05	0.000192	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—JAG1—urinary bladder cancer	1.86e-05	0.000184	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PTEN—urinary bladder cancer	1.81e-05	0.00018	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.78e-05	0.000177	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—MYC—urinary bladder cancer	1.77e-05	0.000175	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—EP300—urinary bladder cancer	1.73e-05	0.000171	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—MYC—urinary bladder cancer	1.69e-05	0.000167	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.61e-05	0.000159	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.52e-05	0.00015	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—S100B—urinary bladder cancer	1.51e-05	0.000149	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—PPARG—urinary bladder cancer	1.49e-05	0.000148	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.48e-05	0.000147	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—CREBBP—urinary bladder cancer	1.43e-05	0.000142	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NCOR1—urinary bladder cancer	1.35e-05	0.000134	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TERT—urinary bladder cancer	1.19e-05	0.000118	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.18e-05	0.000117	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—FGFR3—urinary bladder cancer	1.1e-05	0.000109	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.07e-05	0.000106	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CREBBP—urinary bladder cancer	9.33e-06	9.24e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—RRM2—urinary bladder cancer	9.23e-06	9.15e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IGF1—urinary bladder cancer	9.21e-06	9.13e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ENO2—urinary bladder cancer	8.55e-06	8.47e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	8.55e-06	8.47e-05	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—MYC—urinary bladder cancer	8.51e-06	8.44e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—RHOA—urinary bladder cancer	8.44e-06	8.36e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	8.29e-06	8.22e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—ERBB2—urinary bladder cancer	7.81e-06	7.74e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CXCL8—urinary bladder cancer	7.41e-06	7.34e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IL2—urinary bladder cancer	7.08e-06	7.01e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CCND1—urinary bladder cancer	6.9e-06	6.84e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—NQO1—urinary bladder cancer	6.89e-06	6.83e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MMP9—urinary bladder cancer	6.7e-06	6.64e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CDKN1A—urinary bladder cancer	6.68e-06	6.61e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PTEN—urinary bladder cancer	6.66e-06	6.6e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—EP300—urinary bladder cancer	6.35e-06	6.29e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—SRC—urinary bladder cancer	6.18e-06	6.12e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	5.75e-06	5.69e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MYC—urinary bladder cancer	5.53e-06	5.48e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—EGFR—urinary bladder cancer	5.41e-06	5.36e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—TYMS—urinary bladder cancer	5.34e-06	5.29e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	5.28e-06	5.23e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	5.28e-06	5.23e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—KRAS—urinary bladder cancer	5.11e-06	5.07e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GPX1—urinary bladder cancer	5.06e-06	5.01e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	4.97e-06	4.92e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	4.67e-06	4.62e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TP53—urinary bladder cancer	4.55e-06	4.5e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—HRAS—urinary bladder cancer	4.35e-06	4.31e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PPARG—urinary bladder cancer	3.78e-06	3.75e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	3.64e-06	3.6e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	2.98e-06	2.95e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.6e-06	2.57e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.48e-06	2.45e-05	CbGpPWpGaD
